^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer

Published date:
10/29/2020
Excerpt:
In the prospective START-TKI study blood samples from 41 patients with EGFR-mutated NSCLC treated with EGFR-TKIs were available. Next generation sequencing (NGS) on cfDNA was performed,...In thirteen (second line) osimertinib-treated patients with a (plasma or tissue) concomitant TP53 mutation at baseline, PFS was significantly shorter compared to six wild-type cases; 8.8 vs. 18.8 months, p = 0.017. 
DOI:
10.3390/cancers12113179
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

1344P - The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the German CRISP registry

Published date:
09/14/2020
Excerpt:
Median PFS of 3rd generation TKI in 2nd and further lines was 9 (n=33) vs. 13 (n=45) months for TP53 mt+ vs. WT (HR 0.461; p<0.005). Median OS of 3rd generation TKI in 2nd line therapy was 24 vs. 41 months, for TP53 mt+ vs. WT (HR 0.514; p<0.126). Median OS of 3rd generation TKI in 2nd and further lines was 14 vs. 26 months for TP53mt+ vs. WT (HR 0.483; p<0.029)....TP53 co-mutations have a negative impact on PFS and OS in EGFR mt+ NSCLC IV patients treated with 3rd generation TKI (Osimertinib) in 2nd line and 2nd/further lines.